• Conference will play host to 15 leading blockchain-focused companies in addition to leading industry experts
• Following the highly successful LD Micro Invitational, a three-day microcap conference held between June 8-10, 2021
• LD Micro Invitational’s organizers have opted to make all presenting companies’ video calls available for three months

SRAX (NASDAQ: SRAX) a digital marketing pioneer focused on providing consumer data management services, has announced that it will be hosting the inaugural Sequire Blockchain Conference on July 15, 2021 (https://ibn.fm/3WTkI). The single-day event, which is set to be take place between 11:30am ET – 5:30pm ET, will play host to over 15 leading blockchain and crypto-focused companies, followed by keynotes with some of the industry’s leading experts. In addition to educating attendees about the various commercial possibilities in the blockchain industry, the conference will also seek to assist participants in unlocking new investment opportunities within the sector. Boasting a network of over five million influential, forward-thinking investors and shareholders as well as 183 publicly listed corporate subscribers, the Sequire platform has established a strong reputation as a venue where investors can congregate to learn, share, and network on a wide range of industry related topics. In that vein, SRAX and Sequire have devised an extensive conference series designed to offer added value to their budding investor community. “We are excited to kick off our conference series and to provide our Sequire clients a platform to reach a large audience of both retail and institutional investors,” stated SRAX CEO and Founder Christopher Miglino in relation to Sequire’s conference series. “Community is a very important part of Sequire, and both virtual and in person events are an integral part of the investor community we are building.” Sequire’s conference series was inaugurated by the Sequire Cannabis Conference in April 2021. Most recently, the series has continued with the 2021 LD Micro Invitational (https://ibn.fm/Xw1bT), a prominent three-day virtual investor conference, held on June 8 – 10, 2021. In addition to featuring over 190 microcap companies, including the best performing companies from the LD Hall of Fame, the event also played host to a myriad of influential keynote speakers, including the likes of Jaime Rogozinski, Rishi Khanna, Matt Hulsizer, Laurie Segall & Liz Claman. Following the conference, LD Micro Invitational’s organizers have opted to make all the presenting companies’ video calls available to the general public to view for a three-month period. The corporate presentations as well as the keynote addresses can be viewed at https://ldmicrojune2021.mysequire.com/. Sequire’s extensive and diverse conference series ranks amongst the various strategies employed by parent company SRAX to augment and streamline their operations over the past few months. Other measures undertaken by the Company include naming entrepreneur and 2020 presidential candidate Brock Pierce to the Company’s board of directors, as well as divesting an equity stake in TI Health (formerly known as SRAXmd). As illustrated by the recent LD Micro Invitational conference’s success, and with Sequire’s popularity rising to new heights among both corporate issuers and investors alike, SRAX stands well poised for continued growth. Additional details on Sequire’s Blockchain Conference, including registration details, can be found at https://blockchain21.mysequire.com/. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Health and wellness product marketer HempFusion Wellness, Inc. is seeing a renewed optimism for a healthy lifestyle amid the ongoing difficulties posed by the COVID-19 pandemic, including a resumption of international orders from lockdown countries
• The company recently announced the expansion of its products through subsidiary Probulin Probiotics, which now has a distribution channel in Ireland and expectations of broader reach into the European Union
• HempFusion Wellness sees its probiotics advances as a way of making in-roads for its CBD products in otherwise reluctant markets worldwide, using its focus on regulatory compliance to build brand confidence
• Co-founder and CEO Jason Mitchell recently discussed the company’s history and the challenges plus benefits of regulatory compliance in an appearance on the Hemp Barons podcast

As Ireland experiences a growing surge in interest in cannabidiol (“CBD”) products, the government is working to ensure compliance with its laws by individuals and small companies, particularly where ingestible food-type substances are concerned. A short webinar presented by The Food Safety Authority of Ireland (“FSAI”) June 24 discussed the legal situation governing the sale of cannabis/hemp products as food in the European Union and specifically in Ireland, with a Q&A session to help resolve any questions about the complex legal requirements in the arena (https://ibn.fm/aFR8u). Health and wellness supplement innovator HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO)  has made compliance with regulatory standards for hemp-derived products worldwide one of its chief priorities, opening doors to outlets for its products through major food and drug retail stores and physician pipelines while many other CBD companies without that focus have been left to search for alternative entries into the competitive marketplace. The company recently announced its product entry to the Irish marketplace through Boots Ireland, a pharmacy-led health and beauty retailer affiliated with the Walgreens Boots Alliance global enterprise (https://ibn.fm/QUYuF), which carries the wholly owned HempFusion subsidiary Probulin Probiotics, LLC. HempFusion’s products include OTC items like topicals designed to meet consumer needs for pain relief, eczema, acne and wound care, as well as CBD tinctures, creams and targeted support capsules for sleep, stress and balanced energy. Probulin Probiotics was launched by HempFusion co-founder and CEO Jason Mitchell in 2013 to provide product solutions for gut health support and skin care. Mitchell described his journey as an entrepreneur in a June 29 Hemp Barons podcast, noting his transformation from a staunch just-say-no approach to cannabinoids in medicine, to an avid advocate for hemp-based wellness solutions, as a result of his own health experiences. “Probiotics are … a valuable area,” Mitchell told podcast host Joy Beckerman (https://ibn.fm/vOx4E). “It’s also an area where it helps you digest your food, it helps you with absorption of nutrients. The gut microbiome is involved in immune function. There’s just so many different things that we underestimate. Even in emotional health, there’s a gut-brain connection.” Mitchell summarized, “For me, helping people understand how important probiotics are was more about my inspiration because of my condition — not because probiotics cured my condition — but instead (it led me to) say, ‘Hey, take care of your gut, because if you don’t, if your gut fails you the rest of your body fails.’ … And I want to encourage people to do it right.” Mitchell and Beckerman also extensively discussed the regulatory journey CBD dietary supplements, as well as OTC cosmetic topicals, have taken under guidance from the U.S. federal government, given HempFusion’s strict emphasis on compliance with legal frameworks. “The fact is, it’s really fun to do it right, because it’s challenging. And then when you see the consumer response that they get the result they want, and that you did it correctly … they’re going to have a tremendous amount of trust in you and have longevity in their support of your brand,” Mitchell said. “And so that’s why we did it. We create this brand loyalty by virtue of doing it right.” The company’s efforts to sustain confidence in its brand have resulted in the resumption of business in international markets (and entry into Ireland) following the struggles associated with the era of COVID-19 pandemic lockdowns. “To see them coming back alive gives me encouragement,” Mitchell said. “Not just for my company. … It’s just that people are starting to come back out, feel safe, secure. People are healthy.” For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• Greenhouse production continues to be the no. 1 tool for reducing initial operational costs.
• The report analyzed five years of data to identify key trends in the cannabis cultivation market.
• The average cost to grow a pound of dried flower was $396 for warehouse cultivation sites, only $233 for greenhouse sites.

According to a recent five-year study of the cannabis industry, greenhouse production is a leading choice for cannabis cultivation companies (https://ibn.fm/yULMF). The report, published by “Cannabis Business Times,” reaffirms the business strategy of Hero Technologies (OTC: HENC), a cannabis company that is focused on growing into a multistate, vertically integrated entity with strong cultivation and dispensary assets. “Greenhouse production continues to be the no. 1 tool for reducing your initial and operational costs for a 52-week production facility, as illustrated in this year’s report showing a decrease in indoor and increase in greenhouse cultivation sites,” states the “2020 State of the Industry” report. “Nearly a third of greenhouse cultivators also report average production costs of less than $100 per pound of dried flower, compared to 11% of indoor cultivators.” The report carefully analyzed five years of data to identify key trends in the cannabis cultivation market. Key findings from the report include the consistent move from warehouse, or inside, cultivation to greenhouse, or outdoor, cultivation; a trend toward bigger operations and more facilities; and the average cost comparison to grow a pound of dried flower between greenhouse and warehouse sites. “The year-over-year percentage changeshowing where people grow cannabis —warehouse/indoors, greenhouse or outdoors — was negligible when comparing 2019 to 2020,” the report noted. “When looking further back in time, the number of people growing cannabis in warehouses has decreased by 20 percentage points since the first ‘State of the Cannabis Cultivation Industry’ study in 2016, when a vast majority (80%) of participants grew indoors compared with 60% in this year’s study. Meanwhile, the number of participants growing in greenhouses and outdoors has increased steadily over the years, with some variations.” The report went on to observe that “most participants operate single cannabis growing operations (59%), but examining five years of data reveals trends toward larger facilities and more grow sites. In 2016, 66% grew in a single facility/location. Between 2016 and 2020, the number of participants indicating they grow in two or more facilities/grow sites increased from 32% to 41%. “The number of cultivators growing in five or more sites jumped by 5 percentage points compared with the first year of the study, moving from 6% to 11%,” the report continued. “In addition, the number of cultivators who have 80,000 sq. ft. or more of production space has increased by 12 percentage points comparing the 2016 to 2020 studies, and now nearly a fifth of study participants (19%) indicate they grow in facilities that size or larger.” The trend toward greenhouse cultivation is understandable when looking at the bottom line. The report noted that, in 2020, the average cost to grow a pound of dried flower was $396 for warehouse or indoor cultivation sites, and more than $150 less — or $233 — to grow the same amount in a greenhouse. These numbers are welcome news for Hero Technologies, which has a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal conditions in greenhouses to enhance photosynthesis and produce large flowering plants. The system addresses some of today’s most relevant challenges with cannabis cultivation by featuring robust odor-control systems, proprietary zero-waste growing systems, and the lowest carbon footprint of any industry standards. Hero Technologies Inc. is a cannabis company working toward a vertically integrated business model. The company’s strategic business plan includes cannabis genetic engineering, space for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed
• Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distribution
• Report incorporates both CYB001 and CYB004 into valuation

As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy, people are paying attention. A recent Stifel report raised Cybin’s price target by C$12, up from C$4 to C$15, and maintained the company’s speculative buy rating (https://ibn.fm/HLcxX). “CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, including CYB004, with the announcement of two chosen indications, Social Anxiety Disorder (‘SAD’) and Generalized Anxiety Disorder (‘GAD’), some of the most common mental illnesses in the U.S,” the investment firm reported in its release. “We note CYB004 is a 2nd generation deuterated psychedelic molecule, offering strong potential for IP protection and a long period of outsized returns, in our view. “Currently, management expects CYB004 to enter Phase 1 clinical trials H1/22 with further research likely needed before determining whether to combine SAD and GAD into one clinical trial at the outset or to separate the two early on,” the report continued. “We now include CYB004 in our valuation for the first time, raising our target from $11 to $15, and reiterate our SPEC BUY rating given the large disconnect with the market, offering an attractive entry point.” As key points for its decision, Stifel pointed to the company selecting indications with large patient pools, a potentially understated market size, and the potential for multiple synergies across development and distribution. “CYBN has selected Social Anxiety Disorder (‘SAD’) and Generalized Anxiety Disorder (‘GAD’) as the initial target indications for its novel and proprietary psychedelic molecule CYB004,” the report stated. “SAD and GAD affect 3–7% of the U.S. population, putting both indications in line with the prevalence of Major Depressive Disorder, in our view, and representing a large potential patient pool.” Stifel pointed out that the global pandemic potentially increased these numbers, “with management indicating a 3-fold increase and the CDC suggesting symptoms of an anxiety or depressive disorder increased from 36.4% to 41.5% during the Aug. 2020–Feb. 2021 period (already in the height of the pandemic) with the percentage of those reporting an unmet mental health care need increased from 9.2% to 11.7%.” As for market size, the report noted that “whilemanagement indicated a potential global market size of ~US$4b for both indications combined, we believe the opportunity could be markedly higher. We note these estimates are based on the patient population seeking treatment with first-line therapy utilizing SSRI/SNRI antidepressants. However, we believe a majority of the patient population either does not seek treatment or does not receive appropriate treatment. . . . Hence, should CYB004 prove to be a more effective alternative with less side effects, its addressable market size could be larger than what we see currently.” Finally, Stifel also observed thatpatients dealing with anxiety commonly also have psychiatric co-morbidities with up to 80% of GAD patients also suffering from another mood disorder during their lifetime. “More specifically, we believe there could be a 50–60% probability that patients suffering from an anxiety disorder also have Major Depressive Disorder (‘MDD’). This could be a reason why antidepressants became a first-line treatment. Given CYBN’s primary drug candidate (‘CYB001’) focuses on MDD, we believe there are considerable drug development synergies where both clinical trials could share information, distribution/marketing channels, and have an overall higher chance of success,” the report stated. “We are incorporating CYB004 into our valuation for the first time through a 10-year, 2-stage DCF analysis with main assumptions including: successful launch FY28, pricing in-line with CYB001 & Spravato at ~$53k, addressing only the most severe anxiety cases, terminal growth of 2% and discount rate of 25%,” the report concluded. “As a result, our target increases from $11 to $15. SPEC BUY.” Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• The buyer loaded an initial 200.52 barrels of heavy crude and paid WTI pricing of $70.91 per barrel of crude oil produced at the company’s Asphalt Ridge facility
• Samples of the Asphalt Ridge crude are being sent to Quadrise Fuels International Plc in the UK for assessment to determine if it is suitable for the British company’s proprietary technology
• Petroteq and Greenfield are working with a local drilling fluids company for the identification of customers for the clean sand produced for use as a potential frac sand

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF), an oil company focused on developing and implementing its proprietary oil extraction and reclamation technologies, has announced that the oil it produced at its Asphalt Ridge facility (the POSP) at the beginning of June 2021 has been sold and handed over to its buyer (https://ibn.fm/nJIYR). According to a company press release, the buyer paid West Texas Intermediate (‘WTI”) pricing of $70.91 per barrel, resulting in a net realized price of $57.91 per barrel after removing transportation costs of $13 per barrel. Due to trucking weight limitations, the buyer was only able to load 200.52 barrels of the10.2° API heavy crude produced at Asphalt Ridge. Commenting on the oil acquisition, George Stapleton, Petroteq COO, stated, “The fact that we were able to receive WTI pricing for the oil produced by the POSP demonstrates that the heavy, sweet (low sulfur) oil produced from Utah’s tar sands will likely command a premium price relative to other heavy oils. There also appears to be a market for our produced sand, which is a bonus.” The clean sands produced by the POSP can potentially be used as frac sand. Petroteq and Greenfield Energy, a 50/50 joint venture between TomCo Energy plc (AIM: TOM) and Valkor LLC, are currently working with a local drilling fluids company to identify customers for these clean sands. To date, the fluids company has taken an initial 40 tons and is expected to take an additional 700 tonnes over the coming weeks. Proceeds from this sand sale are expected to total approximately $15-$20 per ton. To further explore market opportunities for its produced oil, Petroteq is preparing a sample of its produced oil to ship to Quadrise Fuels International Plc in the UK. The purpose is to assess if the heavy, sweet oil produced by the POSP will be suitable for Quadrise’s MSAR(R) technology, a low viscosity oil-in-water emulsified synthetic heavy fuel oil obtained by mixing heavy residual oils with water and specific chemicals in a proprietary formulation. The sample is expected to leave the U.S. by the end of June 2021. Testing will be taking place following its arrival in the UK. Petroteq is engaged in developing and implementing its patented, proprietary technology that allows for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits, and shallow oil deposits while also expanding operations at the Asphalt Ridge facility. The source is nearer the surface and avoids the risk found in traditional drilling. Unlike traditional fracking, Petroteq’s technology focuses on heavy oil, which is currently in high demand. Most refineries are required to take a mixture of heavy and light oils, allowing them to provide a wide range of products, but Petroteq is uniquely positioned to help satisfy the heavy-oil gap. Petroteq’s green technology uses a small, modular footprint, which produces no greenhouse gases, does not require high temperatures, leaves only clean dry sand, and could be used to help unlock heavy oil deposits worldwide. Despite setbacks from the COVID-19 pandemic, the global oil demand is expected to rise to 104 million barrels per day (mb/d) by 2026, increasing 4% over 2019 totals (https://ibn.fm/xwP3w). To meet the oil growth demand, the supply will need to rise by 10 mb/d by the IEA’s projected date. For more information, visit the company’s website at www.Petroteq.com. NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• Drug delivery platform developer Lexaria Bioscience has been testing its patented technology in conjunction with antivirals Remdesivir and Ebastine during the past year to determine the potential for enhancing their effectiveness against the COVID-19 virus
• Early-stage testing has determined Lexaria’s technology — DehydraTECH — did not inhibit Remdesivir and Ebastine in their use against the virus
• DehydraTECH is a technology that helps drugs gain better bioavailability through effective introduction into patients’ bloodstreams
• The DehydraTECH platform has also shown great potential in enhancing hypertension medication and additional trials are ongoing

Pharmaceutical use and bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) recently reported it has achieved a major milestone in efficacy testing in combination with antiviral drugs that comprise a significant weapon in the war against COVID-19 infections, enhancing Lexaria’s potential for eventually partnering with a major pharmaceutical company as a drug delivery platform. Lexaria’s patented DehydraTECH technology strives to make swallowed pharmaceuticals more potent in their bloodstream bioavailability through creation of a select formulation that rivals the efficacy some substance users achieve only through smoking or inhaling products into the lungs — a potentially dangerous means of activating a drug’s potential. The company has reported trial successes working with blood pressure drugs and antivirals. Lexaria’s latest accomplishment involves testing DehydraTECH for the delivery of Remdesivir and Ebastine — antivirals that have gained renown in their use to reduce the harm wrought by COVID-19 SARS-CoV-2 during the past year’s global pandemic. In an in vitro IC50 study that measures the amount of a drug necessary to inhibit a biological process (https://ibn.fm/HgxOf) — specifically the amount of Remdesivir and Ebastine necessary to deliver a potent response against the COVID-19 SARS-CoV-2 virus — researchers found that DehydraTECH use as a delivery platform “did not negate the known efficacy of those compounds” (https://ibn.fm/VCm4E). While the testing is simply an early-stage analysis of whether DehydraTECH reduces the effectiveness of these drug treatments, Lexaria regards the successful results as an indicator that it is on the right track in seeking entry to the antiviral market, which is expected to achieve sales revenues of $44 billion within the next five years, according to analysts at by Global Market Insights Inc. (https://ibn.fm/5fpvp). Even before the advent of the COVID virus pandemic, health conditions such as influenza, HIV, respiratory syncytial virus (“RSV”), allergic rhinitis and other coronaviruses were expected to drive the market higher with a CAGR of 3.2 percent (https://ibn.fm/8TyOU) and Lexaria isn’t limiting its antiviral scope to studies involving COVID-19 drugs. “We needed to know if DehydraTECH(TM) interferes in any way with the effects these drugs have on the virus,” Lexaria Bioscience CEO Chris Bunka stated. “It doesn’t give us any direct score on ‘how well’ it works or does not, just a yes-no. The next step is to move on to in vivo efficacy testing in animals and then eventually humans.” However, testing has revealed that circulating drug levels of Remdesivir and Ebastine, enabled by DehydraTECH, were measured at two or three times their concentration levels in the non-DehydraTECH controls, providing Lexaria with the best results the company has “ever generated demonstrating our technology’s ability to more effectively deliver antiviral drugs when taken orally,” Bunka stated. When used with cannabidiol (“CBD”) in testing for hypertension strategies, the DehydraTECH-enhanced substance delivered a 5 percent drop in blood pressure after a single 90mg dose and a 300 percent greater concentration of CBD in under 30 minutes in 2018. A Phase I trial of the drug — HYPER-H21-1 — was completed ahead of schedule in June (https://ibn.fm/iLnR3) and that launch of Phase II trials was subsequently announced to determine time series blood pressure and heart rate effect. Lexaria has licensed its technology for use by a number of companies and has plans to also study DehydraTECH’s performance with non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors, human hormones, and vitamins. The company reported on its progress to investors at the Life Sciences Investor Forum conference series on June 24. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Infobird was featured in a recent SmallCapsDaily article that encouraged tech investors to grab IFBD’s stock as it looks to be a very compelling investment proposition
• This favorable outlook follows two new agreements announced within ten days and which represent the company’s diversification into the retail industry
• Infobird also expects its 2021 revenue will grow by 50% to between $22-$25 million
• The company is keen on accelerating the promotion of its marketing, customer service, and other related products in the retail industry

Infobird (NASDAQ: IFBD) was recently featured in an article by leading financial news website and publisher, SmallCapsDaily (https://ibn.fm/kJ6qB). Observing that the cloud computing domain commands the highest valuation, the piece notes that it has become extremely difficult to find reasonably priced stocks with cloud-oriented business models, particularly within the software-as-a-service (“SaaS”) market. Yet, IFBD trades at a “very cheap valuation, even below its IPO.” Even so, the article sheds light on a few elements that have not been factored into the current valuation, leading to the lower-than-expected valuation. These elements position IFBD as a very compelling investment proposition. Founded in 2001 and headquartered in Beijing, China, Infobird has grown over the years. It transitioned from its focus on call center services into a full-fledged tech solutions provider of customized AI-enabled, cloud-based customer engagement management solutions, having shifted from its initial standardized SaaS module model to a customized SaaS format recently. At the outset, Infobird, which also offers cloud-based sales force management software solutions, dealt primarily with companies in the financial services industry but has since expanded its focus into other sectors – its most recent diversification move is its entry into the retail industry. “Recently,” reads the article (https://ibn.fm/BSnPd) “Infobird issued two press releases announcing that it was awarded two new client assignments with large and well-known customers in the retail industry, a clear sign that the company is successfully executing its strategy of entering this new large and growing industry sector.” The Chinese retail sector has indeed witnessed growth over the last two decades. Valued at 3.9 trillion yuan ($557 billion at current exchange rates) in 2000, the sector grew to 36 trillion yuan ($5.6 trillion) in 2020 (https://ibn.fm/W0LA3). It is expected to expand further at an annual growth rate of 12.4% in 2021 and 7.1% in 2022 (https://ibn.fm/tnEZC). Through its strategic move, Infobird intends to help its clients achieve performance growth, in effect mirroring the sector’s upward trend. Further, as a company that is now committed to accelerating the promotion of its marketing, customer service, and other related products in the retail industry, these two assignments with Zu Li Jian and SaSa Cosmetics (China) Co., Ltd demonstrate its diversification strategy and cement its entry into this growing sector. Notably, the impact of this strategy extends beyond Infobird’s and its clients’ locus as it sends a clear message that IFBD “is aiming for the sky and is not expected to slow down its growth initiatives.” The article, which further notes that the announcement points to an undervaluation of IFBD’s stock, encourages tech investors to quickly seize the opportunity while the profitable SaaS stock is still cheap. “This [diversification] strategy, together with the expectation from the company that revenues for fiscal 2021, ending December 31, 2021, will be between $22 million and $25 million, an expected growth rate of more than 50% is why the company looks to be a very compelling investment proposition,” the article continues. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Company’s first line of NFTs features 17 unique pieces of artwork designed to highlight diversity within the music industry
• Each NFT opens royalty opportunities to holders for a catalog of over 50 different songs performed by top artists, including Rhianna, Justin Timberlake, Cher, Beyonce, Jay-Z, and Jane Zhang
• One ETH purchases an NFT and entry into the Music Mogul Club, offering exclusive membership benefits. The first 2100 NFT buyers gain access to the Music Mogul Club and additional membership benefits
• Staking into the royalty pools will begin in July 2021, with stakers earning royalties as early as Q3 2021

“Every Time It’s Played” is an appropriate name for the first line of non-fungible tokens (“NFTs”) released by entertainment fintech company and musi industry disruptor BAND Royalty, as the company’s music catalog offers over 50 songs that earn royalties for NFT holders every time they are played. The catalog includes songs performed by famous artists such as Rhianna, Justin Timberlake, Cher, Beyonce, Jay-Z, and Jane Zhang. The artists are not directly affiliated with BAND Royalty, which simply owns the royalties for the songs, allowing for royalty revenue whenever a song is played, no matter who the performer. The company’s first series of NFTs is currently for sale beginning at 1 ETH and also features 17 unique art pieces. The art represents the diversity in the music industry and is unique for this first line of NFTs. In addition, buyers who purchase an NFT for 1 ETH also gain access to BAND Royalty’s new Music Mogul Club. The first 2100 NFT buyers gain access to additional membership benefits. The Music Mogul Club offers NFT holders:

• Access to exclusive concerts
• Exclusive BAND merch
• First access to new NFTs
• Exclusive access to backstage events
• Festival passes
• Discounts on concerts
• Exclusive prize draws

Buyers can purchase NFTs through the company’s first-ever Music Only NFT Marketplace at https://bandroyalty.com/buynfts. After completing the purchase, users can register their NFT into the Music Mogul Club to take advantage of the exclusive member benefits. The access to the club opened in June 2021. As of July 2021, users can stake their NFT purchases in one of three royalty pools:

1. Publishing Royalties Pool
2. Mechanical and Public Performance Royalties Pool
3. Music Synchronization Royalties Pool

Each NFT must be staked for a minimum of 90 days, up to a maximum of five years. Stakers will be able to begin collecting royalties during Q3 2021. Stakers can earn up to 50% of royalties every time a song in the BAND Royalty catalog is played across all media channels. The current NFT series consists of eight different rarity levels for a total of only 3,000 NFTs. The largest is the Vinyl Album level (1,500 NFTs at 1 ETH each), stakeable in one royalty pool. Vinyl Gold Album (750 NFTs at 3 ETH each) and Gold Album (500 NFTs at 5 ETH) are stakeable in two royalty pools. Gold Platinum (225 NFTs at 7.5 ETH each) and Platinum Album (22 NFTs at 10 ETH each) are stakeable in all three royalty pools. The rarest categories – Platinum Diamond Album, Diamond Album, and Double Diamond Album, consisting of one NFT each at prices ranging from 15 to 25 ETH and, with access to all three royalty pools and tokens, are already sold out. The company intends to release up to 12,000 unique tokens across four series in the near future. The next series of NFTs is expected as early as July 2021. All revenue from these upcoming series will be used to expand BAND’s royalty library. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

Since being founded in 2017, the USA CBD Expo has established itself as the United States and South America’s leading CBD and Hemp conference series. Organizers of the show have routinely hosted hundreds of vendors from across the CBD value chain, the sector’s most significant brands as well as influential thought leaders and speakers. The most recent iteration of the USA CBD Expo was held at Atlanta’s immense Georgia World Congress Center – the third-largest convention center in the United States – between June 11-13^th, 2021, and proved to be a resounding success by all accounts, attracting thousands of attendees, over 300 vendors, and approximately 50 expert speakers drawn from across the CBD and hemp sectors. The state of Georgia, whose legal landscape currently allows medical marijuana consumers access to low-tetrahydrocannabinol (“THC”) CBD, boasts a slightly more permissive legal framework relative to its neighbors Alabama, Tennessee, and the Carolinas, which regard cannabis as fully illegal, and Florida, which has legalized medical marijuana for patients with select conditions. The progressive legal backdrop coupled with the growth of the industry within the state were all key factors influencing the conference’s location upon its return to an in-person format. This month’s Atlanta USA CBD Expo was split into two key sessions. The first day and a half were devoted to a B2B-only networking and investment-friendly get-together, followed by a subsequent one-and-a-half-day session focused on the event’s demos, buying opportunities, seminars, and keynote speakers. The conference once again distinguished itself for its multi-disciplinary offering, playing host to a diverse set of speakers, ranging from government insiders to advocates for veteran rights and benefits. Catering to a diverse audience comprised of both industry professionals as well as the general public, the seminars covered a variety of topics including an overview of the regulatory environment for CBD in Georgia, prospects for the CBD and hemp sectors going forward, as well as an in-depth analysis into the diverse business verticals within the industry. The USA CBD Expo series will next be held in Chicago between October 28-30, 2021. Seeking to bring together a rapidly expanding industry into a single, global trade show experience, the USA CBD Expo is committed to producing the best show possible to best advertise their exhibitors’ businesses, drive traffic to their respective booths, and get them closer to potential customers and new business ventures. For more information on future events, visit www.USACBDExpo.com.

• Nextech AR Solutions, a diversified leading provider of augmented reality (“AR”) experience technologies and services, is developing a platform for creating and publishing 3D images – at scale – from 2D originals, facilitating the digital transformation of online shopping and education
• Nextech recently announced the closing of its acquisition of AI 3D image mass producer Threedy.ai in an all-stock transaction valued at $9.5 million
• The combined efforts of the companies will remove a key bottleneck for e-commerce operators and manufacturers to create 3D models of their products at scale so that they can be easily marketed online via Web AR and on other smart devices
• Nextech’s immersive learning and video conference solution announced in June supports educators’ needs in transforming traditional learning and event formats into interactive digital learning experiences

Augmented reality (“AR”) ecosystem developer Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) has been making a name for itself developing 3D interactive experiential solutions that it expects to enhance e-commerce’s and higher education adoption and engagement. While the company’s AR platform may still be a little ways away from the capability of the intergalactic holographic video conferencing envisioned long ago by Hollywood’s “Star Wars” creator, Nextech is nonetheless advancing users’ ability to project human holograms and market products through 3D visualizations in cell phones, Web and other smart tech devices. Nextech’s potential to scale its 3D product took a significant leap in June when it closed on the acquisition of Silicon Valley-based artificial intelligence (“AI”) company Threedy.ai, Inc. The deal, finalized through the issuance of company shares valued at $9.5 million, will help Nextech toward its goal of creating “a disruptive, fully integrated, AR/AI enabled and scalable 3D modeling platform” suited to e-commerce customers, according to the company (https://ibn.fm/0Vzqk). “Retailers including Kohl’s, Pier1 and K-Mart Australia are already using Threedy’s technology to offer AR shopping experiences at scale and now together with Nextech we will create a unified, scalable 3D content creation engine for all our AR solutions,” Threedy CEO Nima Sarshar stated (https://ibn.fm/2j2td). “Threedy has created AI-powered tools that take 3D content creation for AR and other applications from a craft-production process to mass-production. It takes several hours for a typical 3D artist to create a 3D replica of a physical product. Content creation has long been the bottleneck for bringing AR to large retailers, many of whom have thousands of SKUs live at any given time. Using our virtual assembly line technology, thousands of models can be created per week, with minimal human intervention, in many categories.” Nextech’s technology stack also facilitates a more humanistic feel for the video-conferenced meetings that have become practically ubiquitous during the past year as a result of the COVID-19 pandemic. That includes educational solutions, as evidenced by Nextech’s announcement of its EdTechX solution the launch in June. The platform provides educational institutions with the technological means to turn their virtual experiences into evolved-beyond-the-white-board opportunities (https://ibn.fm/oDn8b). For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF